| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5104547 | Value in Health | 2017 | 11 Pages |
Abstract
Compared with other oral direct-acting antiviral agents, EBR/GZR ± RBV was the economically dominant regimen for treating GT1a noncirrhotic and GT1b TN cirrhotic patients, and was cost saving in all other populations.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Shelby PharmD, MS, BCPS, Elamin H. PhD, Steven N. MPH, Chizoba PhD,